ProCE Banner Activity

Clinical Dilemma: A Patient With a Diagnosis of Stage IV NSCLC-NOS Is Referred to You for a Second Opinion

Clinical Thought
In the age of targeted therapies and immune checkpoint inhibition, Leora Horn, MD, MSc, FRCPC, discusses the importance of avoiding diagnoses of lung cancer–not otherwise specified in the optimal treatment of patients with newly diagnosed, advanced NSCLC.

Released: November 21, 2016

Expiration: November 20, 2017

No longer available for credit.

Share

Faculty

Leora Horn

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Genentech, Lilly, and Merck.